Research & Development
Legend Biotech has a broad portfolio of autologous and allogeneic product candidates targeting hematologic malignancies and solid tumors.
Legend Biotech has a broad portfolio of autologous and allogeneic product candidates targeting hematologic malignancies and solid tumors.
We explore several innovative and evolving technologies to treat blood and solid cancers: autologous chimeric antigen receptor T-cell therapy (CAR-T); and allogeneic CAR-T, natural killer (NK) cells and gamma-delta (γδ) T cells. As a global team, we are building a fully integrated cell therapy platform and advancing multiple agents in the process.
Today we have multiple therapeutic candidates in development built on our R&D team's three core strengths:
We have in-house antibody screening and engineering capabilities
Diverse allogeneic platforms, including non-gene editing universal CAR-T and NK, which may offer benefits in safety and CMC production
Multiple armoring strategies to overcome challenges in treating solid tumors
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.